Ammar Al-Chalabi
LightNews LightNews
banner
ammaralchalabi.bsky.social
Ammar Al-Chalabi
@ammaralchalabi.bsky.social
740 followers 750 following 36 posts
Professor of Neurology and Complex Disease Genetics, King's College London. Co-Director UK MND Research Institute https://ukmndri.org #MND #ALS Specialist. Deputy Editor, Brain
Posts Replies Media Videos
ammaralchalabi.bsky.social
People with #ALS #MND with respiratory compromise should be offered COVID immunization by their GPs.

united2endmnd.org/2025/11/14/c...
Covid-19 Boosters in the UK – Statement
Covid-19 Boosters in the UK – Statement This autumn is the first since the Joint Committee on Vaccination and Immunisation (JCVI) changed its policy on who can receive Covid-19 vaccination bo…
united2endmnd.org
November 14, 2025 at 3:08 PM
Reposted by Ammar Al-Chalabi
ukmndri.bsky.social
Drug development is a complex and costly process.

By using medicines approved for other conditions, we can overcome barriers in drug development.

Read our blog explaining why we believe repurposed drugs could help us find new treatments for #MND/#ALS.

ukmndri.org/2025/11/13/r...
Repurposed Drugs: Accelerating MND Treatment Discovery
Discover how repurposed drugs are helping accelerate the search for effective treatments for MND through innovative UK research.
ukmndri.org
November 14, 2025 at 9:34 AM
Reposted by Ammar Al-Chalabi
ukmndri.bsky.social
Yesterday, we attended @mndoddie5.bsky.social's Discovery Network Showcase 2025.

Researchers, clinicians, industry partners, and people affected by #MND/#ALS discussed how the network can drive forward progress in better understanding MND and the development of new treatments.
November 13, 2025 at 1:59 PM
Reposted by Ammar Al-Chalabi
ukmndri.bsky.social
Our Co-Director, Prof. @ammaralchalabi.bsky.social, gave a fantastic talk yesterday, hosted by @mndassoc.bsky.social, on #MND/#ALS genetics, why they matter and how discoveries are shaping new treatments.

Thank you to everyone who joined in person & online!
#MNDresearch #genetics
November 5, 2025 at 8:04 PM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
We had the pleasure of catching up with Dr Brian Dickie MBE (@bd365.bsky.social), Chief Scientist at the @mndassoc.bsky.social, the principal funder of the £7.5M Longitude Prize on ALS.

📖 Read the full Q&A here: bit.ly/3KTi1Ap
October 21, 2025 at 11:18 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
Join us at the #ASHG25 Annual Meeting in Boston, starting today!

Visit us at Booth 46, we’d love to meet you and discuss how the ~$10M Longitude Prize on ALS is harnessing #AI to transform the future of neurodegenerative disease treatment.

@challengeworks.bsky.social @geneticssociety.bsky.social
October 14, 2025 at 9:56 AM
ammaralchalabi.bsky.social
We must find an effective treatment for #ALS #MND

@ukmndri.bsky.social

BBC News - Former England captain Moody reveals MND diagnosis
www.bbc.com/sport/rugby-...
Lewis Moody: Former England captain reveals motor neurone disease diagnosis
Former England captain Lewis Moody reveals he has been diagnosed with motor neurone disease in an exclusive BBC interview.
www.bbc.com
October 6, 2025 at 7:32 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
⏰ 2 months to go until applications close for the £7.5 million Longitude Prize on ALS.

You could help transform treatment for neurodegenerative diseases like hashtag #ALS, the most common form of motor neurone disease ( #MND ).

Learn more: bit.ly/4mlzSg5
October 3, 2025 at 3:09 PM
Reposted by Ammar Al-Chalabi
end-the-legacy.bsky.social
Connect with us at #NealsMtg ! We are thrilled to be joining the NEALS meeting once again in person this coming week. For anyone impacted by ALS virtual registration is free. Cheers to NEALS for such an open policy. See more at https://meeting.neals.org/ . #EndtheLegacy #NEALS
October 3, 2025 at 12:26 PM
ammaralchalabi.bsky.social
This is a landmark paper showing a predictive test for #ALS #MND up to 40 years before onset and able to predict age of onset. Huge implications

www.nature.com/articles/s41...
A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis - Nature Medicine
Plasma proteomic analysis of presymptomatic individuals with amyotrophic lateral sclerosis identifies novel disease-associated proteins and enables the development of an accurate diagnostic biomarker ...
www.nature.com
August 29, 2025 at 8:05 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
🌍 Be part of the global effort to tackle #ALS.

The £7.5m (~$10m) #LongitudePrizeOnALS is searching for innovators in #AI, #data, #biotech, and #neurology.

🧠 Meet the teams already registered, and find out how you can partner with them below.

🔗https://bit.ly/4mdHxxX
August 12, 2025 at 1:56 PM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
🧠 The @ukmndri.bsky.social is an #MND powerhouse, accelerating progress towards new treatments and, ultimately, a cure.

Read their article about how the #LongitudePrizeOnALS could be a game-changer for drug discovery in neurodegenerative diseases.

🔗 bit.ly/40Tmmsh

@ammaralchalabi.bsky.social
Longitude Prize launched to accelerate AI-driven drug discovery
A new international challenge prize has been launched to transform drug discovery for ALS, the most common form of MND through AI.
ukmndri.org
August 5, 2025 at 9:16 AM
Reposted by Ammar Al-Chalabi
dementiaresearcher.bsky.social
Postdoc Research Assistant in Dr Arpan Mehta’s lab at University of Dundee, using CRISPR screens in iPSC-derived motor neurons to study ALS mechanisms. Closing date: 4th August

www.dementiaresearcher.nihr.ac.uk/job/postdoc-...
Postdoc Research Assistant: Investigating C9ORF72
Postdoc Research Assistant in Dr Arpan Mehta’s lab at University of Dundee, using CRISPR screens in iPSC-derived motor neurons to study ALS mechanisms.
www.dementiaresearcher.nihr.ac.uk
July 23, 2025 at 8:38 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
“MND is one of the most scientifically and biologically challenging diseases to tackle. That said, no mountain is insurmountable…”

Dr. Mike Rogers (@mndassoc.bsky.social) shares why the #LongitudePrizeOnALS is key to creating new opportunities for #ALS & #MND

📰 longevity.technology/news/climbin...
Climbing the ALS mountain
Mike Rogers, MND Association Director of Research and Innovation, looks at how data and AI could unlock new treatments.
longevity.technology
July 22, 2025 at 8:54 AM
Reposted by Ammar Al-Chalabi
smcgrath.phd
Tagging 🧪 🧬🖥️
scientificdiscovery.dev Saloni @scientificdiscovery.dev · Jul 19
Sad news:

The dataset behind this famous chart on the decline in costs of genome sequencing has had its NIH funding cut.

I loved this chart because it was the first that made me appreciate the impact of dataviz. But it also tracked progress towards an ambitious goal ($1000 genome) that succeeded.
NHGRI (at NIH)'s chart on the declining cost of sequencing a human genome from 2001 to 2021, falling faster than Moore's law. The "$1,000 genome" catchphrase was first publicly recorded in December 2001 at a scientific retreat to discuss the future of biomedical research following publication of the first draft of the Human Genome Project (HGP), convened by the National Human Genome Research Institute at Airlie House in Virginia.[5] The phrase neatly highlighted the chasm between the actual cost of the Human Genome Project, estimated at $2.7 billion over a decade, and the benchmark for routine, affordable personal genome sequencing. On 2 October 2002, Craig Venter introduced the opening session of GSAC (The Genome Sequencing and Analysis Conference) at the Hynes Convention Center in Boston: "The Future of Sequencing: Advancing Towards the $1,000 Genome." Speakers included George M. Church and executives from 454 Life Sciences, Solexa, U.S. Genomics, VisiGen and Amersham plc.[6][7] In 2003, Venter announced that his foundation would earmark $500,000 for a breakthrough leading to the $1,000 genome.[8] That sum was subsequently rolled into the Archon X Prize. In October 2004, NHGRI introduced the first in a series of '$1,000 Genome' grants designed to advance "the development of breakthrough technologies that will enable a human-sized genome to be sequenced for $1,000 or less."[9]
July 19, 2025 at 1:28 PM
Reposted by Ammar Al-Chalabi
ukmndri.bsky.social
New research has examined how disrupted sleep patterns may signal the early stages of #MND / #ALS or FTD, providing clues to earlier detection.

Read more ⬇️
🔗 ukmndri.org/2025/07/16/r...

This post is part of our Research Snapshot series, powered by Readable Research at @sheffielduni.bsky.social
Could sleep changes signal the early stages of MND or FTD?
Research has found that disrupted sleep may offer some clues to possible early warning signs of the ALS or FTD.
ukmndri.org
July 16, 2025 at 1:23 PM
Reposted by Ammar Al-Chalabi
medicine.stitches.today
Researchers reveal that structural variants disrupting the 3D genome can drive diseases like cancer by altering gene expression.

by Sreenivasan VKA, Yumiceba V and Spielmann M in Nat Rev Genet #MedSky

👉 get more here

📖 read the article:
Structural variants in the 3D genome as drivers of disease - Nature Reviews Genetics
Disruption of the 3D genome caused by structural variation contributes to developmental disorders and cancer. The authors review the causes and molecular and clinical consequences of position effects arising from disruptions to the genome architecture.
www.nature.com
July 9, 2025 at 4:48 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
⏰ Reminder: Our first Welcome Webinar is tomorrow, Tuesday 9th of July at 09:00 BST.

💻 Register below to learn everything you need to know about the #LongitudePrizeOnALS, including how to apply, how the Prize works, and what support is available.
longitudeprize.bsky.social Longitude Prize on ALS @longitudeprize.bsky.social · Jul 2
Want to learn more about the £7.5M #LongitudePrizeOnALS?
Join one of our welcome webinars to find out how the Prize works and how to get involved.

Register here:
📅 9 July, 09:00 BST: bit.ly/4nzJuWA
📅 10 July, 17:00 BST: bit.ly/3Tl4u5u

#AIForGood #MND #ALS
July 8, 2025 at 9:29 AM
Reposted by Ammar Al-Chalabi
dementiaresearcher.bsky.social
Research Fellow vacancy at UCL MND Centre. Join Prof Andrea Malaspina’s team to study immune responses and neoantigens in ALS using proteomics and cell phenotyping. Closing date: 20th July

www.dementiaresearcher.nihr.ac.uk/job/research...
Research Fellow: Glial-immune crosstalk and sporadic ALS
Research Fellow vacancy at UCL MND Centre. Join Prof Andrea Malaspina’s team to study immune responses & neoantigens in ALS using proteomics & cell phenotyping
www.dementiaresearcher.nihr.ac.uk
July 6, 2025 at 8:53 PM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
🧠 As the principal funder, the @mndassoc.bsky.social has been instrumental in bringing the #LongitudePrizeOnALS to life.

We were joined by Dr Usman Khan last week, who spoke on the power of cross-specialism collaboration.

Learn more about the Prize: bit.ly/4kD3tSh

#AIforGood #MND #ALS
July 3, 2025 at 11:20 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
Want to learn more about the £7.5M #LongitudePrizeOnALS?
Join one of our welcome webinars to find out how the Prize works and how to get involved.

Register here:
📅 9 July, 09:00 BST: bit.ly/4nzJuWA
📅 10 July, 17:00 BST: bit.ly/3Tl4u5u

#AIForGood #MND #ALS
July 2, 2025 at 9:56 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
Check out this article from Dr Brian Dickie (@mndassoc.bsky.social), exploring how #AI and quality data can transform treatment progress—and how the £7.5M #LongitudePrizeonALS aims to support #innovation through global collaboration.

🧠 Read here: bit.ly/4nqi4lN
#ALS #MND
Motor neurone disease affects one in 300, but hope for treatment is growing
One in 300 of us will develop motor neurone disease in our lifetime. It is a hideous disease that robs a person of their dignity and eventually their life.
bit.ly
June 30, 2025 at 9:00 AM
Reposted by Ammar Al-Chalabi
dementiaresearcher.bsky.social
Apply now for the NIHR Senior Investigator award! £15K per year for 4 years to support top researchers shaping the future of health and social care in the UK. @nihr.bsky.social

www.dementiaresearcher.nihr.ac.uk/funding/nihr...
NIHR Senior Investigators Award - DEMENTIA RESEARCHER
Apply for the NIHR Senior Investigator award: £15K per year for 4 years to support leading applied research and shape the future of health and social care.
www.dementiaresearcher.nihr.ac.uk
June 30, 2025 at 8:01 AM
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
What a week for the #LongitudePrizeOnALS 🧠

Thank you to everyone who made it possible!

🎥 Watch the segment on BBC News here: bit.ly/4eoGyaR

This is just the beginning. Entries close 3 Dec → Learn more on our website: bit.ly/4kD3tSh

@trisdyson.bsky.social @ammaralchalabi.bsky.social #AIforGood
What an incredible week! | Longitude Prize on ALS
What an incredible week! Thank you to everyone who helped make the launch of the #LongitudePrizeOnALS such a success — from the inspiring voices on stage, to the teams that made this Prize possible, ...
www.linkedin.com
June 27, 2025 at 11:37 AM
Reposted by Ammar Al-Chalabi
dementiaresearcher.bsky.social
Join Dr Arpan Mehta's lab at MRC PPU, Dundee, for a 12-month postdoc using CRISPR screens to explore ALS in iPSC-derived motor neurons. Closing date: 18th July

www.dementiaresearcher.nihr.ac.uk/job/postdoc-...
Postdoc Research Assistant: Mechanisms of the C9ORF72
Join Dr Arpan Mehta's lab at MRC PPU, University of Dundee, for a 12-month postdoc using CRISPR screens to explore ALS in iPSC-derived motor neurons.
www.dementiaresearcher.nihr.ac.uk
June 21, 2025 at 8:22 PM